Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Validates Subcutaneous Delivery Technology With Strong Phase I Results

This article was originally published in The Pink Sheet Daily

Executive Summary

The RNA interference-focused biotech will bring the rest of its pipeline forward with subcutaneous technology now that it has been validated in human studies, but the company will continue to pursue approval of its lead candidate as an infusion product.

You may also be interested in...



Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work

RNAi pioneer is getting closer to market with NDA filing in amyloidosis expected in 2017, but ample competition is coming along, albeit far behind.

Alnylam Going After Alexion's Soliris In PNH, Eyes Roche In Hemophilia

At an investor day, the RNAi firm outlined Phase I programs in paroxysmal nocturnal hemoglobinuria, hemophilia and hepatic porphyria, and said it is using a de-risked drug development methodology.

Isis Preps To Advance Two Drugs To Phase III In Rare Diseases

Isis will target its APOCIII candidate to treat extremely and severely high triglycerides first, then move to broader populations. The strategy harkens back to the plan for cholesterol drug Kynamro, which has had a slow launch.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075948

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel